ArticleScientific reports2021
Transgenic refractory Aedes aegypti lines are resistant to multiple serotypes of dengue virus.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 19 citations in OpenAlex.
- Advances in CRISPR gene drives for mosquito population control.Current opinion in microbiology · 2026Review
- Horizons of the Future: Preparedness and Response.Current topics in microbiology and immunology · 2026Review
- Performance of two low-threshold population replacement gene drives in cage populations of the yellow fever mosquito, Aedes aegypti.PLoS genetics · 2025Article
- ExploitingPathogens (Basel, Switzerland) · 2025Review
- Effect of C-type lectin 16 on dengue virus infection inPNAS nexus · 2024Article
- Advances and challenges in synthetic biology for mosquito control.Trends in parasitology · 2024Review
- Engineered Antiviral Sensor Targets Infected Mosquitoes.The CRISPR journal · 2023Article
- Manipulating the Destiny of Wild Populations Using CRISPR.Annual review of genetics · 2023Review
- Mimicking superinfection exclusion disrupts alphavirus infection and transmission in the yellow fever mosquitoProceedings of the National Academy of Sciences of the United States of America · 2023Article
- Engineered Antiviral Sensor Targets Infected Mosquitoes.bioRxiv : the preprint server for biology · 2023Article
- CRISPR mediated transactivation in the human disease vector Aedes aegypti.PLoS pathogens · 2023Article
- Use of Insect Promoters in Genetic Engineering to Control Mosquito-Borne Diseases.Biomolecules · 2022Review
Corrections and comments
- Erratum issued
Authors and funding
15 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The areas where dengue virus (DENV) is endemic have expanded rapidly, driven in part by the global spread of Aedes species, which act as disease vectors. DENV replicates in the mosquito midgut and is disseminated to the mosquito's salivary glands for amplification. Thus, blocking virus infection or replication in the tissues of the mosquito may be a viable strategy for reducing the incidence of DENV transmission to humans. Here we used the mariner Mos1 transposase to create an Aedes aegypti line that expresses virus-specific miRNA hairpins capable of blocking DENV replication. These microRNA are driven by the blood-meal-inducible carboxypeptidase A promoter or by the polyubiquitin promoter. The transgenic mosquitoes exhibited significantly lower infection rates and viral titers for most DENV serotypes 7 days after receiving an infectious blood meal. The treatment was also effective at day 14 post infection after a second blood meal had been administered. In viral transmission assay, we found there was significantly reduced transmission in these lines. These transgenic mosquitoes were effective in silencing most of the DENV genome; such an approach may be employed to control a dengue fever epidemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.